TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE

Objectives: Low-dose cytarabine (LD-AraC) is still regarded as the standard of care in elderly patients with acute myeloid leukemia (AML) ‘unfit’ for intensive chemotherapy. In this study, we compared the efficacy of LD-AraC, in patients ≥ 70 years old, with that of intensive chemotherapy, best supp...

Full description

Bibliographic Details
Published in:	Mediterranean Journal of Hematology and Infectious Diseases
Main Authors:	Maël Heiblig, Mohamed Elhamri, Isabelle Tigaud, Adriana Plesa, Fiorenza Barraco, Hélène Labussière, Sophie Ducastelle, Mauricette Michallet, Franck Nicolini, Claudiu Plesa, Eric Wattel, Gilles Salles, Xavier Thomas
Format:	Article
Language:	English
Published:	PAGEPress Publications 2016-01-01
Subjects:	acute myeloid leukemia low-dose cytarabine treatment elderly prognosis.
Online Access:	http://www.mjhid.org/index.php/mjhid/article/view/2409

Similar Items

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
by: Louise Laloi, et al.
Published: (2023-03-01)

LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY
by: Xavier Thomas, et al.
Published: (2020-04-01)

Toxicity and outcome of adults with acute myeloid leukemia receiving consolidation with high-dose cytarabine
by: Lais Moreira Lopes, et al.
Published: (2024-10-01)

Enhanced Antitumor Efficacy of Cytarabine and Idarubicin in Acute Myeloid Leukemia Using Liposomal Formulation: In Vitro and In Vivo Studies
by: Chunxia Zhu, et al.
Published: (2024-09-01)

Glucose Metabolism as a Potential Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia
by: Joana Pereira-Vieira, et al.
Published: (2024-03-01)

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
by: SV Gritsaev, et al.
Published: (2016-01-01)

Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse‐risk acute myeloid leukaemia: A single‐centre retrospective analysis
by: Bao‐Quan Song, et al.
Published: (2023-11-01)

Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients
by: Gökçen Özcan, et al.
Published: (2021-04-01)

Corneal epithelial microcysts due to high dose Cytarabine administration in acute myeloid leukemia
by: Tuba Hilkay Karapınar, et al.
Published: (2012-03-01)

Interaction of Lipophilic Cytarabine Derivatives with Biomembrane Model at the Air/Water Interface
by: Jhon Fernando Berrio Escobar, et al.
Published: (2022-09-01)

Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling
by: Qiong Su, et al.
Published: (2023-12-01)

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia
by: M.C. Azevedo, et al.
Published: (2015-02-01)

Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities
by: Biao Wang, et al.
Published: (2021-02-01)

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
by: Jason T. Anderson, et al.
Published: (2019-12-01)

Case report: Dysphonia associated with high-dose cytarabine therapy
by: Ling Ma, et al.
Published: (2025-01-01)

Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
by: Tomislav Smoljo, et al.
Published: (2023-10-01)

Validation of CRISPR targeting for proliferation and cytarabine resistance control genes in the acute myeloid leukemia cell line MOLM-13
by: Subhash C Prajapati, et al.
Published: (2022-03-01)

Intermediate-dose cytarabine alone versus combination in consolidation therapy for non-transplant acute myeloid leukemia: a retrospective study
by: Yu Liu, et al.
Published: (2025-12-01)

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
by: Lauro Fabián Amador-Medina, et al.
Published: (2024-12-01)

Diffuse purpuric eruption in a patient with acute myeloid leukemia
by: Zoha K. Momin, BS, et al.
Published: (2023-11-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: Shahriari Ahmadi A, et al.
Published: (2004-08-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: A Shahriari Ahmadi, et al.
Published: (2004-03-01)

Concanavalin A staining: a potential biomarker to predict cytarabine sensitivity in acute myeloid leukemia
by: Tao Zhang, et al.
Published: (2024-01-01)

The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX‐351) in Acute Myeloid Leukemia Patients: A Systematic Review
by: Abdulwahab M. Alzahrani, et al.
Published: (2025-05-01)

IONPs combined with cytarabine downregulated IFITM3 expression to inhibit acute myeloid leukemia
by: Jun Dou, et al.
Published: (2025-09-01)

Enterotoxins A and B produced by Staphylococcus aureus increase cell proliferation, invasion and cytarabine resistance in acute myeloid leukemia cell lines
by: Seyhan Turk, et al.
Published: (2023-09-01)

Prognostication refinement in NPM1‐mutated acute myeloid leukemia stratified by FLT3‐ITD status with different induction doses of cytarabine
by: Biao Wang, et al.
Published: (2023-04-01)

Can pharmacogenetics impact the therapeutic effect of cytarabine and anthracyclines in adult acute myeloid leukaemia patients?: A Serbian experience
by: Pravdić Zlatko, et al.
Published: (2024-01-01)

Bilosomes and Niosomes for Enhanced Intestinal Absorption and In Vivo Efficacy of Cytarabine in Treatment of Acute Myeloid Leukemia
by: Abdelrahman R. Said, et al.
Published: (2024-11-01)

Physiological and histological effects of apigenin and luteolin on Cytarabine injected rats
by: Ghada A. Taqa, et al.
Published: (2024-01-01)

Hand foot syndrome associated with standard dose cytarabine
by: Atul Sharma, et al.
Published: (2013-01-01)

Advanced Photocatalytic Degradation of Cytarabine from Pharmaceutical Wastewaters
by: Alexandra Berbentea, et al.
Published: (2024-05-01)

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
by: Hui‐Jen Tsai, et al.
Published: (2021-05-01)

Cytarabine Induced Reproductive Histopathological Changes in Albino Male Mice
by: Niran A. Ibrahim, et al.
Published: (2017-01-01)

Intake of oligoelements with cytarabine or etoposide alters dopamine levels and oxidative damage in rat brain
by: David Calderón Guzmán, et al.
Published: (2024-05-01)

Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
by: Young Hoon Park, et al.
Published: (2022-07-01)

Tribulus terrestris L. Hydroalcoholic Extract Revokes the Hepatotoxicity Induced by Cytarabine in Male Wistar Rats
by: Niloufar Darbandi, et al.
Published: (2025-03-01)

Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells
by: Petra Otevřelová, et al.
Published: (2021-01-01)

"Time sequential high dose of Cytarabine in acute myelocytic leukemia "
by: Ghavamzadeh A, et al.
Published: (2003-03-01)

Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis
by: Yang Qiu, et al.
Published: (2024-04-01)